Live tape
Top 8, mentions 7d8,657GOOGL1,668 mentions▲ +0.04SNDK1,265 mentions▲ +0.10MRNA1,259 mentions▲ +0.09META1,109 mentions▲ +0.03NVDA1,028 mentions▲ +0.08SPCX889 mentions▲ +0.08NBIS743 mentions▲ +0.09MSFT696 mentions▲ +0.06

Equity · Healthcare

AMRX

Amneal Pharmaceuticals, Inc. · NasdaqGS

$18.19 −1.28% 1D Finazon · prior-day close · Aug 18, 2026
Price · Chart
Our own end-of-day closes 60 sessions
$20 $12 22 May 18 Aug

The line runs $12.41 on 22 May through $18.19 on 18 August, on a scale from $12 to $20. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of AMRX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 60 sessions over that window: $12.41 on 22 May 2026 through $18.19 on 18 August 2026.

Market cap $5.8B
P/E (TTM) 40.4
52-week range $8.82 – $19
Avg volume 408.9K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 19, 2026

AMRX insider trades

SEC Form 4 · last 90 days · newest reported trade 13 Aug 2026
Open-market buys 0
Open-market sells 4
Net sold $7.22M
Non-trade filings 6
Date Insider Type Shares Value
13 Aug 2026 Kiely John Director Sell 50,000 $882K
12 Aug 2026 Daly Jason B. EVP, Chief Legal Officer Sell 210,000 $3.65M
12 Aug 2026 Shah Nikita Executive Vice President Sell 146,403 $2.56M
11 Aug 2026 Daly Jason B. EVP, Chief Legal Officer Sell 6,613 $117K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
13 Aug 2026 Kiely John Director Gift 10,000
11 Aug 2026 BUCHI J KEVIN Director Option exercise 168,573 $2.90M
10 Aug 2026 Patel Tushar Bhikhubhai 10% Owner Award 12,763,469
10 Aug 2026 Patel Chirag K. President & Co-CEO Award 6,381,734
10 Aug 2026 Patel Gautam Director Award 283,632
10 Aug 2026 Patel Chintu Co-CEO Award 6,381,734

AMRX reported financials

SEC EDGAR XBRL

AMRX reported revenue of $3.0B for the fiscal year ended 31 Dec 2025. Net income over the same period was $72.1M.

Figure Reported Period
Revenue $3.0B 31 Dec 2025 fiscal year
Net income $72.1M 31 Dec 2025 fiscal year
Diluted EPS $0.22 31 Dec 2025 fiscal year
Total assets $3.8B 30 Jun 2026 at period end
Total equity $33.0M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

AMRX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.18 —
31 Mar 2026 Q1 2026 $0.19 —
31 Dec 2025 FY 2025 $0.22 —
30 Sep 2025 Q3 2025 $0.01 —
30 Jun 2025 Q2 2025 $0.07 —
31 Mar 2025 Q1 2025 $0.04 —
31 Dec 2024 FY 2024 $-0.38 —
30 Sep 2024 Q3 2024 $0.00 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

AMRX institutional holders

SEC Form 13F

7 of the 45 institutional funds we track reported a AMRX position for the quarter ended 30 Jun 2026 — a combined $59.8M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Citadel Advisors Added +93.7% shares 1,118,715 $19.4M
AQR Capital Management Held (±25%) −8.1% shares 795,028 $13.8M
D. E. Shaw & Co. Trimmed −55.0% shares 774,055 $13.4M
Balyasny Asset Management Added +448.7% shares 434,132 $7.5M
Two Sigma Investments Held (±25%) −17.5% shares 233,270 $4.0M
Renaissance Technologies Trimmed −68.4% shares 87,487 $1.5M
Millennium Management Trimmed −96.0% shares 14,761 $256K
Man Group Exited
Point72 Asset Management Exited

Source: SEC EDGAR 13F filings

AMRX fails-to-deliver

SEC CNS data

On 21 Jul 2026, 13,475 shares of AMRX failed to deliver (about $236K).

Settlement date Shares failed Notional % of shares out
21 Jul 2026 13,475 $236K 0.004%
16 Jul 2026 523 $9K <0.001%

Source: SEC fails-to-deliver (CNS) data